PharmaCyte Biotech, Inc.
PMCB · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $95 | $127 | $118 | $97 |
| G&A Expenses | $753 | $1,821 | $609 | $726 |
| SG&A Expenses | $753 | $915 | $842 | $1,009 |
| Sales & Mktg Exp. | $0 | -$906 | $233 | $283 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $848 | $1,042 | $960 | $1,106 |
| Operating Income | -$848 | -$1,042 | -$960 | -$1,106 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7,512 | $12,791 | -$2,085 | -$363 |
| Pre-Tax Income | -$8,360 | $11,750 | -$3,045 | -$1,470 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,360 | $11,750 | -$3,045 | -$1,470 |
| % Margin | – | – | – | – |
| EPS | -1.23 | 1.6 | -0.44 | -0.39 |
| % Growth | -176.9% | 463.6% | -12.8% | – |
| EPS Diluted | -1.23 | 1.6 | -0.44 | -0.39 |
| Weighted Avg Shares Out | 6,796 | 6,796 | 6,960 | 7,637 |
| Weighted Avg Shares Out Dil | 6,796 | 6,796 | 6,960 | 7,637 |
| Supplemental Information | – | – | – | – |
| Interest Income | $218 | $230 | $256 | $383 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8,360 | -$1,042 | -$960 | -$1,106 |
| % Margin | – | – | – | – |